Clinerion Partners with CCRI
The Czech Clinical Research Institute (CCRI) will support patients and physicians in the Czech Republic and Slovakia in accessing innovative treatments by expanding Clinerion’s hospital and patient coverage into those countries. CCRI will also accelerate the development of innovative medications by offering the services and real-world data solutions of Clinerion’s Patient Network Explorer platform.
Czech Clinical Research Institute (CCRI) is a full-service contract research organization providing tailor-made solutions for clinical trials monitoring, project management and Good Clinical Practice auditing services, operating mainly in the Czech Republic and Slovakia. CCRI also offers a wide-ranging portfolio of life sciences consulting services within the areas of pharmacovigilance, quality control, regulatory affairs consulting, data management and medical writing.
CCRI will support the expansion of Clinerion’s hospital network in the Czech Republic and Slovakia, thereby expanding the coverage of patients in Patient Network Explorer in those countries. CCRI will also offer Patient Network Explorer services and solutions for real-world evidence and accelerating clinical trials to clinical research sponsors and academic researchers.
“CCRI is a great match for Clinerion in the Czech Republic and Slovakia, traditionally countries with high medical expertise and infrastructure but low trial participation,” says Ian Rentsch, CEO of Clinerion. “Expanding the coverage of Patient Network Explorer will bring patients in the two countries to greater attention when sponsors are making siting decisions.”
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Ponsegromab Significantly Improves Body Weight in Patients with Cancer Cachexia
September 17th 2024Results of a Phase II study of ponsegromab showed significant improvements in body weight, muscle function, and overall symptoms for patients with cancer cachexia, offering hope for a new targeted treatment.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
